Amy Tiersten

2.4k total citations
101 papers, 1.6k citations indexed

About

Amy Tiersten is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amy Tiersten has authored 101 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Amy Tiersten's work include Cancer Treatment and Pharmacology (29 papers), Advanced Breast Cancer Therapies (26 papers) and Breast Cancer Treatment Studies (18 papers). Amy Tiersten is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), Advanced Breast Cancer Therapies (26 papers) and Breast Cancer Treatment Studies (18 papers). Amy Tiersten collaborates with scholars based in United States, India and Canada. Amy Tiersten's co-authors include Dawn L. Hershman, Daniel C. McFarland, Jimmie C. Holland, Andrea B. Troxel, Kelly M. Shaffer, Joseph A. Sparano, Rima Patel, Yelena Novik, John Crown and Paula Klein and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Amy Tiersten

90 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Tiersten United States 20 1.0k 324 275 264 211 101 1.6k
Jurandyr Moreira de Andrade Brazil 21 690 0.7× 158 0.5× 290 1.1× 317 1.2× 274 1.3× 114 1.5k
Jane Bryce Italy 19 978 1.0× 408 1.3× 151 0.5× 355 1.3× 83 0.4× 41 1.8k
Uwe Güth Switzerland 22 694 0.7× 178 0.5× 457 1.7× 205 0.8× 143 0.7× 102 1.4k
Scott Ernst Canada 25 741 0.7× 659 2.0× 276 1.0× 553 2.1× 159 0.8× 55 1.8k
Vernon Harvey New Zealand 22 1.3k 1.3× 357 1.1× 489 1.8× 258 1.0× 86 0.4× 44 1.8k
Yeşim Eralp Türkiye 21 555 0.5× 279 0.9× 344 1.3× 186 0.7× 103 0.5× 94 1.3k
Anna Koumarianou Greece 23 937 0.9× 327 1.0× 181 0.7× 305 1.2× 81 0.4× 114 1.7k
Anne M. Noonan United States 27 1.3k 1.2× 396 1.2× 360 1.3× 561 2.1× 354 1.7× 117 2.1k
Stephen Welch Canada 24 1.0k 1.0× 388 1.2× 279 1.0× 626 2.4× 96 0.5× 124 1.9k
Xiaoling Liu China 17 955 0.9× 238 0.7× 282 1.0× 845 3.2× 135 0.6× 57 2.0k

Countries citing papers authored by Amy Tiersten

Since Specialization
Citations

This map shows the geographic impact of Amy Tiersten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Tiersten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Tiersten more than expected).

Fields of papers citing papers by Amy Tiersten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Tiersten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Tiersten. The network helps show where Amy Tiersten may publish in the future.

Co-authorship network of co-authors of Amy Tiersten

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Tiersten. A scholar is included among the top collaborators of Amy Tiersten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Tiersten. Amy Tiersten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patel, Rima, Jami Fukui, Paula Klein, et al.. (2025). Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. Breast Cancer Research and Treatment. 214(2). 159–170.
2.
Patel, Rima, et al.. (2025). The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer. Biomedicines. 13(9). 2209–2209. 1 indexed citations
3.
Bilani, Nadeem, et al.. (2024). Origin associated with heterogeneity amongst Hispanic patients with breast cancer in the United States.. Journal of Clinical Oncology. 42(16_suppl). e23077–e23077.
4.
Montgomery, Guy H., et al.. (2024). A randomized controlled trial of hypnosis to manage musculoskeletal pain in breast cancer survivors taking aromatase inhibitors.. Psychology of Consciousness Theory Research and Practice. 12(4). 649–664.
5.
Tiersten, Amy, et al.. (2024). Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report. Journal of Dermatological Treatment. 35(1). 2336118–2336118. 4 indexed citations
6.
Patel, Rima, et al.. (2024). Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer. Breast Cancer Research and Treatment. 208(2). 461–466. 1 indexed citations
7.
Kessler, Alaina J., Rima Patel, Emily J. Gallagher, et al.. (2024). Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression. Breast Cancer Research and Treatment. 207(3). 529–532. 1 indexed citations
8.
Sheng, Tianxiang, et al.. (2024). Switching from nonsteroidal aromatase inhibitors to exemestane and its impact on menopausal symptoms.. Journal of Clinical Oncology. 42(16_suppl). e13098–e13098.
9.
10.
Lee, Shing Yip, Amy Tiersten, Della Makower, et al.. (2021). Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Research and Treatment. 189(1). 177–185. 22 indexed citations
11.
12.
Zimmerman, Brittney S., Kelly Suchman, Erin Moshier, et al.. (2021). Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26–30 and ≥31. Oncology. 99(11). 699–702. 1 indexed citations
13.
Zimmerman, Brittney S., et al.. (2020). Patient Perception of Telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 Pandemic: A Single Center Survey-based Study. Journal of Breast Cancer. 23(5). 542–542. 51 indexed citations
14.
Muggia, Franco M., James L. Speyer, John P. Curtin, et al.. (2014). A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.. Journal of Clinical Oncology. 32(15_suppl). 5564–5564. 2 indexed citations
15.
Singh, Jasmeet, Matthew Volm, Julia Smith, et al.. (2013). RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial.. Journal of Clinical Oncology. 31(15_suppl). 1042–1042. 3 indexed citations
16.
Adams, Sylvia, Lina Kozhaya, Frank Martiniuk, et al.. (2012). Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer. Clinical Cancer Research. 18(24). 6748–6757. 184 indexed citations
17.
18.
Tiersten, Amy, et al.. (2004). Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecologic Oncology. 92(2). 635–638. 50 indexed citations
19.
Vahdat, Linda T., Casilda Balmaceda, Thomas F. McGovern, et al.. (1998). Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.. PubMed. 4(7). 1689–95. 23 indexed citations
20.
Seidman, Andrew D., Amy Tiersten, Clifford A. Hudis, et al.. (1995). Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.. Journal of Clinical Oncology. 13(10). 2575–2581. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jurandyr Moreira de Andrade Breakdown of academic impact, for papers by Jane Bryce Breakdown of academic impact, for papers by Uwe Güth Breakdown of academic impact, for papers by Scott Ernst Breakdown of academic impact, for papers by Vernon Harvey Breakdown of academic impact, for papers by Yeşim Eralp Breakdown of academic impact, for papers by Anna Koumarianou Breakdown of academic impact, for papers by Anne M. Noonan Breakdown of academic impact, for papers by Stephen Welch Breakdown of academic impact, for papers by Xiaoling Liu
Rankless by CCL
2026